產(chǎn)品屬性：
產(chǎn)品名稱 | SW106065 |
規(guī)格 | 10mM*1 mL in DMSO、5 mg、10 mg、25 mg、50 mg、100 mg |
貨號 | EY-01Y10681 |
Cas No.: 62289-81-0
別名: N/A
化學(xué)名: N/A
分子式: C10H8N2OS
分子量: 204.25
溶解度: DMSO: 100 mg/mL (489.60 mM)
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
SW106065 is an apoptosis inducer in malignant peripheral nerve sheath tumors (MPNST). SW106065 inhibits ATP consumption of sMPNST and other models of MPNST with an EC50 of 1 μM. SW106065 can be used for MPNST research[1].SW106065 (Compound 21, Cpd21) inhibits the human MPNST cell lines growth in a dose-dependent manner, and EC50 concentrations of 439 nM and 753.6 nM for S462 and SNF96.2 cells, respectively. SW106065 remains nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts[1].SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment shows a decreased percentage of cells in S phase, and a corresponding increased percentage in G1/G0 and G2/M[1]. SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment decreases the levels of cyclin A2, cyclin B1, cyclin D1, cyclin E, cdk4, and cdk6. And increases levels of cdkn1a and cdkn2a mRNA were observed in a dose-dependent manner.SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment decreases the levels of Cyclin D1 protein[1].SW106065 (Cpd21) treatment significant increase in the percentage of apoptotic cells[1].Cell Cycle Analysis[1] Cell Line:sMPNST cellsSW106065 (Cpd21; 40 mg/kg; intraperitoneal injection; twice per day for 4 weeks) treatment can be delivered to mice in concentrations to sufficiently penetrate sMPNST tissue, and inhibit tumor development[1].Animal Model:NCR-nu/nu female mice (6-7 week old) injected with MPNST cells[1][1]. Vincent Chau, et al. Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res. 2014 Jan 15;74(2):586-97.
特別提醒公司產(chǎn)品僅供科研使用
